The risk for development of obstructive sleep apnea (OSA) and the severity of disease in patients with multiple sclerosis (MS) may be affected by the location of the lesions.
Among women with active relapsing-remitting multiple sclerosis, continuation of natalizumab treatment until the end of the first trimester is associated with significantly reduced disease reactivation compared with stopping natalizumab at conception.
Limited data are available regarding the satisfaction of patients with MS with their first diagnostic consultation (FDC). The goal of the current retrospective study was to identify FDC factors that may influence patient satisfaction.
Intravenous tissue-type plasminogen activator for acute ischemic stroke may be given to patients with recent or concurrent MI, but consideration should be given to the type of MI and time elapsed between the events.
A study finds that in characterization of peripheral nerve sheath tumors as benign or malignant in patients with neurofibromatosis type 1, MRI-obtained apparent diffusion coefficient and FDG-PET/CT-obtained maximum standardized uptake values are excellent imaging markers.
As most young children with neurofibromatosis type 2 (NF2) do not initially present with vestibular schwannomas, it is important to consider this diagnosis in children with the characteristic ocular abnormalities or a meningioma, according to the largest series of young pediatric patients with NF2.
Increasing white matter hyperintensity volume load may be associated with recurrent stroke after ischemic or hemorrhagic stroke, and with 1-year mortality after ischemic stroke.
Evidence to date suggests that the risk for all-cause dementia is 40% to 60% higher in patients with type 1 or type 2 diabetes.
Rapid outpatient strategy is safe and feasible for management of patients with transient ischemic attack and minor stroke evaluated in the emergency department.
Migraine is a potential risk factor for the development of traumatic brain injury (TBI) and is associated with a 78% increased risk for TBI compared with individuals without migraine.
